|
1
|
Galkina E and Ley K: Immune and
inflammatory mechanisms of atherosclerosis (*). Ann Rev
Immunol. 27:165–197. 2009. View Article : Google Scholar
|
|
2
|
Heinecke JW: Mechanisms of oxidative
damage of low density lipoprotein in human atherosclerosis. Curr
Opin Lipidol. 8:268–274. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Miyakis S, Giannakopoulos B and Krilis SA:
Beta 2 glycoprotein I - function in health and disease. Thromb Res.
114:335–346. 2004. View Article : Google Scholar
|
|
4
|
Kobayashi K, Matsuura E, Liu Q, Furukawa
J, Kaihara K, Inagaki J, Atsumi T, Sakairi N, Yasuda T, Voelker DR
and Koike T: A specific ligand for beta (2)-glycoprotein I mediates
autoantibody-dependent uptake of oxidized low density lipoprotein
by macrophages. J Lipid Res. 42:697–709. 2001.PubMed/NCBI
|
|
5
|
Kobayashi K, Kishi M, Atsumi T,
Bertolaccini ML, Makino H, Sakairi N, Yamamoto I, Yasuda T,
Khamashta MA, Hughes GR, et al: Circulating oxidized ldl forms
complexes with beta2-glyco-protein I: Implication as an atherogenic
autoantigen. J Lipid Res. 44:716–726. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Libby P and Ridker PM: Inflammation and
atherosclerosis: Role of c-reactive protein in risk assessment. Am
J Med. 116(Suppl 6A): 9S–16S. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chang MK, Binder CJ, Torzewski M and
Witztum JL: C-reactive protein binds to both oxidized LDL and
apoptotic cells through recognition of a common ligand:
Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci
USA. 99:13043–13048. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Matsuura E, Kobayashia K, Koikeb T,
Shoenfeld Y, Khamashta MA and Hughes GR: Atherogenic autoantigen:
Oxidized LDL complexes with beta2-glycoprotein I. Immunobiology.
207:17–22. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang R, Zhou SJ, Li CJ, Wang XN, Tang YZ,
Chen R, Lv L, Zhao Q, Xing QL, Yu DM and Yu P: C-reactive
protein/oxidised low-density lipoprotein/β2-glycoprotein I complex
promotes atherosclerosis in diabetic BALB/c mice via
p38mitogen-activated protein kinase signal pathway. Lipids Health
Dis. 12:422013. View Article : Google Scholar
|
|
10
|
Lopez LR, Hurley BL, Simpson DF and
Matsuura E: Oxidized low-density lipoprotein/beta2-glycoprotein I
complexes and autoantibodies in patients with type 2 diabetes
mellitus. Ann NY Acad Sci. 1051:97–103. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tabuchi M, Inoue K, Usui-Kataoka H,
Kobayashi K, Teramoto M, Takasugi K, Shikata K, Yamamura M, Ando K,
Nishida K, et al: The association of c-reactive protein with an
oxidative metabolite of LDL and its implication in atherosclerosis.
J Lipid Res. 48:768–781. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Meuwissen M, van der Wal AC, Niessen HW,
Koch KT, de Winter RJ, van der Loos CM, Rittersma SZ, Chamuleau SA,
Tijssen JG, Becker AE and Piek JJ: Colocalisation of intraplaque C
reactive protein, complement, oxidised low density lipoprotein, and
macrophages in stable and unstable angina and acute myocardial
infarction. J Clin Pathol. 59:196–201. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Goldstein JL, Basu SK and Brown MS:
Receptor-mediated endocytosis of low-density lipoprotein in
cultured cells. Methods Enzymol. 98:241–260. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Laplante P, Amireault P, Subang R, Dieudé
M, Levine JS and Rauch J: Interaction of β2-glycoprotein I with
lipopolysaccharide leads to Toll-like receptor 4 (TLR4)-dependent
activation of macrophages. J Biol Chem. 286:42494–42503. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu Q, Kobayashi K, Furukawa J, Inagaki J,
Sakairi N, Iwado A, Yasuda T, Koike T, Voelker DR and Matsuura E:
Omega-carboxyl variants of 7-ketocholesteryl esters are ligands for
beta (2)-glycoprotein I and mediate antibody-dependent uptake of
oxidized ldl by macrophages. J Lipid Res. 43:1486–1495. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang WL, Meng ZX, Zhou SJ, Li CJ, Chen R,
Lv L, Ma ZJ, Yu DM and Yu P: Reduced beta2-glycoprotein I protects
macrophages from ox-LDL-induced foam cell formation and cell
apoptosis. Lipids Health Dis. 12:1742013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ji SR, Wu Y, Potempa LA, Qiu Q and Zhao J:
Interactions of C-reactive protein with low-density lipoproteins:
Implications for an active role of modified C-reactive protein in
atherosclerosis. Int J Biochem Cell Biol. 38:648–661. 2006.
View Article : Google Scholar
|
|
18
|
Chang MK, Hartvigsen K, Ryu J, Kim Y and
Han KH: The pro-atherogenic effects of macrophages are reduced upon
formation of a complex between C-reactive protein and
lysophosphatidylcholine. J Inflamm (Lond). 9:422012. View Article : Google Scholar
|
|
19
|
Moore KJ and Freeman MW: Scavenger
receptors in atherosclerosis: Beyond lipid uptake. Arterioscler
Thromb Vasc Biol. 26:1702–1711. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang X, Collins HL, Ranalletta M, Fuki IV,
Billheimer JT, Rothblat GH, Tall AR and Rader DJ: Macrophage ABCA1
and ABCG1, but not SR-BI, promote macrophage reverse cholesterol
transport in vivo. J Clin Invest. 117:2216–2224. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Matsuura E, Atzeni F, Sarzi-Puttini P,
Turiel M, Lopez LR and Nurmohamed MT: Is atherosclerosis an
autoimmune disease? BMC Med. 12:472014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dinarello CA: Interleukin-1 in the
pathogenesis and treatment of inflammatory diseases. Blood.
117:3720–3732. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Muslin AJ: MAPK signalling in
cardiovascular health and disease: Molecular mechanisms and
therapeutic targets. Clin Sci (Lond). 115:203–218. 2008. View Article : Google Scholar
|
|
24
|
Pearson G, Robinson F, Beers Gibson T, Xu
BE, Karandikar M, Berman K and Cobb MH: Mitogen-activated protein
(MAP) kinase pathways: Regulation and physiological functions.
Endocr Rev. 22:153–183. 2001.PubMed/NCBI
|
|
25
|
Li FX and Li SS: Effects of
andrographolide on the activation of mitogen activated protein
kinases and nuclear factor-κB in mouse peritoneal
macrophage-derived foam cells. Chin J Integr Med. 18:391–394. 2012.
View Article : Google Scholar
|
|
26
|
Weber C and Noels H: Atherosclerosis:
Current pathogenesis and therapeutic options. Nat Med.
17:1410–1422. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kobayashi K, Lopez LR, Shoenfeld Y and
Matsuura E: The role of innate and adaptive immunity to oxidized
low-density lipoprotein in the development of atherosclerosis. Ann
NY Acad Sci. 1051:442–454. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Meisinger C, Baumert J, Khuseyinova N,
Loewel H and Koenig W: Plasma oxidized low-density lipoprotein, a
strong predictor for acute coronary heart disease events in
apparently healthy, middle-aged men from the general population.
Circulation. 112:651–657. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tsuzura S, Ikeda Y, Suehiro T, Ota K,
Osaki F, Arii K, Kumon Y and Hashimoto K: Correlation of plasma
oxidized low-density lipoprotein levels to vascular complications
and human serum paraoxonase in patients with type 2 diabetes.
Metabolism. 53:297–302. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lopez LR, Simpson DF, Hurley BL and
Matsuura E: OxLDL/beta2GPI complexes and autoantibodies in patients
with systemic lupus erythematosus, systemic sclerosis and
antiphospholipid syndrome: Pathogenic implications for vascular
involvement. Ann NY Acad Sci. 1051:313–322. 2005. View Article : Google Scholar
|
|
31
|
Kasahara J, Kobayashi K, Maeshima Y,
Yamasaki Y, Yasuda T, Matsuura E and Makino H: Clinical
significance of serum oxidized low-density
lipoprotein/beta2-glycoprotein I complexes in patients with chronic
renal diseases. Nephron Clin Pract. 98:c15–c24. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Greco TP, Conti-Kelly AM, Anthony JR,
Greco TJ, Doyle R, Boisen M, Kojima K, Matsuura E and Lopez LR:
Oxidized-LDL/beta (2)-glycoprotein I complexes are associated with
disease severity and increased risk for adverse outcomes in
patients with acute coronary syndromes. Am J Clin Pathol.
133:737–743. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sherer Y and Shoenfeld Y: Mechanisms of
disease: Atherosclerosis in autoimmune diseases. Nat Clin Pract
Rheumatol. 2:99–106. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu Y, Kong X, Zhou H, Zhang X, Liu J, Yan
J, Xie H and Xie Y: OxLDL/β2GPI/anti-β2GPI complex induced
macrophage differentiation to foam cell involving TLR4/NF-KappaB
signal transduction pathway. Thromb Res. 134:384–392. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Han KH, Hong KH, Park JH, Ko J, Kang DH,
Choi KJ, Hong MK, Park SW and Park SJ: C-reactive protein promotes
monocyte chemoattractant protein-1-mediated chemotaxis through
upregulating CC chemokine receptor 2 expression in human monocytes.
Circulation. 109:2566–2571. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Devaraj S, Kumaresan PR and Jialal I:
Effect of C-reactive protein on chemokine expression in human
aortic endothelial cells. J Mol Cell Cardiol. 36:405–410. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Galve-de Rochemonteix B, Wiktorowicz K,
Kushner I and Dayer JM: C-reactive protein increases production of
IL-1 alpha, IL-1 beta and TNF-alpha, and expression of mRNA by
human alveolar macrophages. J Leukoc Biol. 53:439–445.
1993.PubMed/NCBI
|
